In-vitro activity of LY146032 against gram-positive isolates from cancer patients.
The in-vitro activity of LY146032 was compared with that of other antibiotics against Gram-positive organisms, mostly isolated from cancer patients. LY146032 inhibited all isolates, including methicillin-resistant Staphylococcus aureus and Streptococcus faecalis, at a concentration of less than or equal to 2.0 mg/l. The MBCs of this new drug were within eight times the MICs for all bacteria tested.
Saito
H
H
Department of Medical Specialties, University of Texas M. D. Anderson Hospital and Tumor Institute, Houston 77030.
Rolston
K V
KV
Ho
D H
DH
LeBlanc
B
B
Bodey
G P
GP
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D017576:Daptomycin; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D006801:Humans; D008826:Microbial Sensitivity Tests; D009369:Neoplasms / Q000382:microbiology; D010455:Peptides / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D010455:Peptides; D017576:Daptomycin